Winship Cancer Institute

And researchers have known for some time that at least some neuroendocrine tumors can express GLP-1 receptors.

Dr. Pohine-Ear, an associate professor at Emory University and Winship Cancer Institute, is an expert in neuroendocrine tumor biology and has conducted extensive research on GLP-1 receptors in human neuroendocrine tumors.

Why they are often in the news now is because the new GLP-1 drugs, these are fantastic molecules that are very effective at helping people to control their diabetes and their obesity and overall has improved the lives of many, many people.

So that's why it's really a very hot topic at the moment.

We'll link the full expert consensus statement on the NETRF webpage for this episode, along with a transcript.

For anyone who would like to learn more, or use it as a resource when talking with their care team.

We spoke with one of its lead authors, Dr. Udavir Grewal, a GI and neuroendocrine medical oncologist at Winship Cancer Institute of Emory University.

A lot of our patients have increasingly turned to us for advice, whether these agents are safe, what could they do to determine the risk associated with these agents.

We have a great faculty today, Dr. Aditya Bardia from the UCLA Health Johnson Comprehensive Cancer Center in Los Angeles.

Dr. Kevin Kalinske from the Winship Cancer Institute of Emory University in Atlanta, and Dr. Joyce O'Shaughnessy from Texas Oncology and the Sarah Cannon Research Institute in Dallas.

As always, we will be discussing the use of unapproved agents and regimens, so check out the package inserts for more information.

We basically have divided this up into three sections, and for each one, The faculty is going to give a short presentation summarizing some of the key papers.

And researchers have known for some time that at least some neuroendocrine tumors can express GLP-1 receptors.

Dr. Pohine-Ear, an associate professor at Emory University and Winship Cancer Institute, is an expert in neuroendocrine tumor biology and has conducted extensive research on GLP-1 receptors in human neuroendocrine tumors.

Why they are often in the news now is because the new GLP-1 drugs, these are fantastic molecules that are very effective at helping people to control their diabetes and their obesity and overall has improved the lives of many, many people.

So that's why it's really a very hot topic at the moment.

We'll link the full expert consensus statement on the NETRF webpage for this episode, along with a transcript.

For anyone who would like to learn more, or use it as a resource when talking with their care team.

We spoke with one of its lead authors, Dr. Udavir Grewal, a GI and neuroendocrine medical oncologist at Winship Cancer Institute of Emory University.

A lot of our patients have increasingly turned to us for advice, whether these agents are safe, what could they do to determine the risk associated with these agents.

Cancer centers share their creative solutions to challenges in patient care and operations, and ACCC members engage directly with these award winners at the ACCC National Oncology Conference to bring those successful strategies back to apply at their own cancer centers.

Today, a preview of an ACCC Innovator Award-winning program by Winship Cancer Institute at Emory University.

Dr. Teresa Gillespie is a professor in the School of Medicine at Emory University and Associate Director for Community Outreach and Engagement at Winship Cancer Institute.

Thanks, Teresa, for joining us.

What challenge was your team looking to solve?

So a big problem is that the Winship Cancer Institute is in the city of Atlanta, which is in a very... urban metro area.

And then all around the rest of the state are 120 rural counties.

So our challenge was how to best reach these rural populations that were at a distance.

Please join me and Stephanie as we discuss oncology nurse navigation with Emily Beard.

Emily currently serves as an oncology survivorship navigator at the Winship Cancer Institute at Emory University.

Honestly, you know, I thought I was going into nursing to become a midwife.

That was kind of what I had thought, you know, when I was a nursing student that I would end up doing.

Well, the extra goes to the hair because they're the second fastest growing cells and it kills it.

As a matter of fact, I just had a conversation with Emory Hospital and Winship Cancer Institute,

which

is part of Emory.